Kymera Therapeutics (KYMR) shares were up 2.5% in recent Monday trading after Wells Fargo upgraded the stock's rating to overweight.
The firm has a price target of $57 for the company.
Trading volume stood at over 187,000 shares against a daily average of about 418,000 shares.
Price: 48.01, Change: +1.16, Percent Change: +2.47
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。